title: [Anti-inflammatory therapy in cystic fibrosis].
abstract: Cystic fibrosis lung inflammation is early, sustained and severe and would justify an anti-inflammatory treatment. At present, the inhaled corticosteroid treatment did not give evidence of efficacy, contrary to the oral presentation, but at the cost of side effects. Azithromycin gives more encouraging results with a good tolerance. New molecules are in the process of validation.
authors.affiliation: Hôpital d'Enfants, rue Morvan, 54511 Vandaeuvre-les-Nancy, France. j.derelle@chu-nancy.fr
authors.forename: J
authors.initials: J
authors.lastname: Derelle
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007249:Inflammation
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D017963:Azithromycin